

Company: "SOPHARMA" AD

Board of Directors: Ognian Donev, PhD
Vessela Stoeva
Alexander Tchaoushev
Bissera Lazarova
Ivan Badinski

Executive Director: Ognian Donev, PhD

Procurator: Simeon Donev

Finance Director: Boris Borisov

Chief Accountant: Jordanka Petkova

Head of Legal Department Alexander Yotov

Registered Office: Sofia
16, Iliensko Shousse Str.

Lawyers: Ventsislav Stoev
Stefan Vachev

Servicing Banks: KBS Bank
DSK Bank EAD
Eurobank and FG Bulgaria AD
ING Bank N.V.
UniCredit AD
Citibank N.A.

Auditors: Baker Tilly Clitou and Partners OOD

"SOPHARMA" AD**INDIVIDUAL STATEMENT OF COMPREHENSIVE INCOME****for the period ended on 31 December 2022**

	Notes	2022 BGN'000	2021 BGN'000
Revenue	3	230 763	200 154
Other operating income/(losses), net	4	5 927	4 131
Changes in inventories of production and work in progress		10 093	(792)
Raw materials and consumables used	5	(80 882)	(64 851)
Hired services expense	6	(35 784)	(35 001)
Employee benefits expense	7	(52 445)	(46 086)
Depreciation and amortisation expense	15,16	(18 189)	(17 545)
Other operating expenses	8	(11 934)	(4 335)
Profit from operations		47 549	35 675
Net (loss) / gain on sale of investments in subsidiaries and associates	18,19	(1 124)	(11 073)
Impairment of non-current assets outside the scope of IFRS 9	10	(2 899)	(4 719)
Finance income	11	4 853	8 615
Finance costs	12	(3 111)	(1 589)
Finance income / (costs), net		1 742	7 026
Profit before income tax		45 268	26 909
Income tax expense	13	(4 885)	(2 638)
Net profit for the year		40 383	24 271
Other comprehensive income:			
<i>Items that will not be reclassified to profit or loss:</i>			
Subsequent valuations of defined benefit pension plan liabilities	33	522	(53)
Subsequent revaluations of property, plant and equipment	15	(991)	8 298
Net change in fair value of other long-term equity investments	20	(1 047)	(355)
Income tax related to components of other comprehensive income that will not be reclassified	13	99	(830)
Other comprehensive income for the year, net of tax	14	(1 417)	7 060
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		38 966	31 331
Basic earnings per share	28	0,33	0,19

The accompanying notes on pages 5 to 147 from an integral part of the individual financial statements.

Executive Director:

Ognian Donev

Finance Director:

Boris Borisov

Chief Accountant:

Jordanka Petkova

"SOPHARMA" AD

INDIVIDUAL STATEMENT OF FINANCIAL POSITION

as at 31 December 2022

	Notes	31 December 2022 BGN'000	31 December 2021 BGN'000
ASSETS			
Non-current assets			
Property, plant and equipment	15	217 834	205 090
Intangible assets	16	4 247	4 324
Investment property	17	49 267	47 302
Investments in subsidiaries	18	90 235	80 598
Investments in associates and joint ventures	19	69 372	54 485
Other long-term equity investments	20	4 706	5 706
Long-term receivables from related parties	21	63 714	49 695
Other long-term receivables	22	3 526	9 546
		502 901	456 746
Current assets			
Inventories	23	82 621	63 222
Receivables from related parties	24	78 345	87 706
Trade receivables	25	19 549	26 631
Loans granted to third parties	26 (a)	8 317	1 804
Other receivables and prepayments	26 (6)	6 182	7 372
Cash and cash equivalents	27	4 762	15 618
		199 776	202 353
TOTAL ASSETS		702 677	659 099
EQUITY AND LIABILITIES			
EQUITY			
Basic share capital		134 798	134 798
Treasury shares		(52 203)	(50 284)
Reserves		461 449	439 040
Other capital components		12 488	12 512
Retained earnings		44 797	28 137
	28	601 329	564 203
LIABILITIES			
Non-current liabilities			
Long-term bank loans	29	11 729	6 750
Deferred tax liabilities	30	4 781	6 389
Government grants	31	3 587	4 007
Liabilities under leasing contracts to related parties	32	14 739	-
Liabilities under leasing contracts to third parties	33	570	496
Long-term liabilities to staff	34	4 192	4 794
		39 598	22 436
Current liabilities			
Short-term bank loans	35	8	46 663
Trade payables	36	41 133	12 671
Payables to related parties	37	2 615	1 609
Tax payables	38	930	700
Payables to personnel and for social security	39	9 398	8 034
Other current liabilities	40	7 666	2 783
		61 750	72 460
TOTAL LIABILITIES		101 348	94 896
TOTAL EQUITY AND LIABILITIES		702 677	659 099

The accompanying notes on pages 5 to 147 from an integral part of the individual financial statements.

Executive Director:

Ognian Donev

Finance Director:

Boris Borisov

Chief Accountant:

Jordanka Petkova

"SOPHARMA" AD

INDIVIDUAL STATEMENT OF CASH FLOWS
for the period ended on 31 December 2022

	Notes	2022 BGN'000	2021 BGN'000
Cash flows from operating activities			
Cash receipts from customers		294 491	249 114
Cash paid to suppliers		(146 506)	(104 150)
Cash paid to employees and for social security		(50 198)	(44 657)
Taxes paid (except income taxes)		(6 743)	(9 201)
Taxes refunded (except income taxes)		4 544	1 262
(Paid)/income taxes refunded, net		(4 921)	(4 055)
Paid interest and bank charges on working capital loans		(898)	(1 027)
Exchange rate differences, net		(222)	(136)
Other proceeds/(payments), net		(576)	(682)
Net cash flows from operating activities		88 971	86 468
Cash flows from investing activities			
Purchases of property, plant and equipment		(12 327)	(6 210)
Proceeds from sales of property, plant and equipment		539	125
Purchases of intangible assets		(588)	(1 128)
Purchased of investment property		(340)	(4 201)
Proceeds from sales of investment property		-	1 952
Purchases of shares in associates		(16 481)	(20 800)
Proceeds from sale of shares in associates		-	354
Purchases of equity investments		(675)	(22 338)
Proceeds from sales of equity investments		628	2 040
Purchases of shares and stakes in subsidiaries		(10 860)	(8 472)
Proceeds from sale of shares and stakes in subsidiaries		515	1 382
Loans granted to related parties		272	594
Loan repayments by related parties		1 215	-
Loans granted to other companies		33	268
Interest received on loans granted		(59 272)	(8 010)
Dividend proceeds from investments in subsidiaries		45 684	11 806
Dividend proceeds from investments in associates		-	(500)
Dividend proceeds from long-term capital investments		-	4 098
Interest received on granted loans		975	2 658
Proceeds from charges under guarantees		243	147
Net cash flows from / (used in) investment activities		(50 439)	(46 235)
Cash flows from financing activities			
Proceeds/ Repayment from long-term bank loans		11 732	-
Repayment of long-term bank loans		(9 677)	(2 428)
(Repayment) / Proceeds from short-term bank loans (overdraft), net		(47 460)	(19 925)
Interest and charges paid under investment purpose loans		-	(81)
Proceeds from sales of treasury shares		-	-
Treasury shares		(1 919)	(16 628)
Dividends paid and unexercised warrants		(11)	(22)
Payments under leasing contracts to third parties		(1 327)	-
Government grants received for agricultural land		(839)	(1 900)
Proceeds from rights sold under warrants		34	81
Proceeds / (payments), net, related to other capital components (warrants)		79	12 512
Net cash flows (used in) / from financial activities		(49 388)	(28 391)
Net decrease in cash and cash equivalents		(10 856)	11 842
Cash and cash equivalents at 1 January		15 618	3 776
Cash and cash equivalents at 31 December	27	4 762	15 618

The accompanying notes on pages 5 to 147 from an integral part of the individual financial statements.

Executive Director:

Ognian Donev

Finance Director:

Chief Accountant:

Boris Borisov

Jordanka Petkova

"SOPHARMA" AD

INDIVIDUAL STATEMENT OF CHANGES IN EQUITY

for the period ended on 31 December 2022

	Notes	Share capital	Treasury shares	Statutory reserves	Revaluation reserve - property, plant and equipment	Reserve from financial assets at fair value through other comprehensive income	Additional reserves	Other capital components (reserve for issued warrants)	Retained earnings	Total equity
		BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000
Balance at 1 January 2021	28	134 798	(33 656)	63 335	21 594	2 282	321 596	-	27 039	536 988
Changes in equity for 2021										
Effects of sold and repurchased treasury shares, incl:		-	(16 628)	-	-	-	-	-	-	(16 628)
- sold treasury shares		-	-	-	-	-	-	-	-	-
- acquisition of treasury shares		-	(16 628)	-	-	-	-	-	-	(16 628)
Other capital components, incl.		-	-	-	-	-	-	12 512	-	12 512
- emission value		-	-	-	-	-	-	12 579	-	12 579
- transaction costs		-	-	-	-	-	-	(67)	-	(67)
Distribution of profit for:		-	-	2 866	-	-	20 985	-	(23 851)	-
- reserves		-	-	2 866	-	-	20 985	-	(23 851)	-
Total comprehensive income for the year, incl:		-	-	-	7 468	(355)	-	-	24 218	31 331
- net profit for the year		-	-	-	-	-	-	-	24 271	24 271
- other comprehensive income, net of taxes		-	-	-	7 468	(355)	-	-	(53)	7 060
Transfer to retained earnings		-	-	-	(448)	(283)	-	-	731	-
Balance at 31 December 2021	28	134 798	(50 284)	66 201	28 614	1 644	342 581	12 512	28 137	564 203
Changes in equity for 2022										
Effects of sold rights on issued warrants		-	(1 919)	-	-	-	-	-	-	(1 919)
Effects of rights sold under issued warrants		-	-	-	-	-	-	-	103	103
Other capital components, incl.		-	-	-	-	-	-	(24)	-	(24)
- transaction costs		-	-	-	-	-	-	(24)	-	-
Distribution of profits for:		-	-	2 427	-	-	22 574	-	(25 001)	-
- reserves		-	-	2 427	-	-	22 574	-	(25 001)	-
Total comprehensive income for the year, incl:		-	-	-	(892)	(1 047)	-	-	40 905	38 966
- net profit for the year		-	-	-	-	-	-	-	40 383	40 383
- other comprehensive income, net of taxes		-	-	-	(892)	(1 047)	-	-	522	(1 417)
Transfer to retained earnings		-	-	-	(616)	(37)	-	-	653	-
Balance at 31 December 2022	28	134 798	(52 203)	68 628	27 106	560	365 155	12 488	44 797	601 329

The accompanying notes on pages 5 to 147 from an integral part of the individual financial statements.

Executive Director:
Ognian Donev

Finance Director:
Boris Borisov

Chief Accountant:
Jordanka Petkova

